Nyxoah, S.A. (NYXH) - Forward Price-to-Revenue Multiple

nyxoah.com (NYXH) - corporate logo

Nyxoah S.A. generates revenue from the sale of implants for patients with apnea who cannot tolerate masks. The projected price-to-sales ratio reflects the dynamics of this demand, with this metric standing at 2.70. Growth is supported by the authority of Genio systems and patent protection for unique nerve stimulators, which create significant barriers to entry for competitors in the neurostimulation segment.

NYXH nyxoah.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/18/2026

Nyxoah - analytical breakdowns and key metrics (NYXH)

- market price and analyst price targets:
- market capitalization indicators:
General company analysis:NYXH (Nyxoah S.A)
Original product of nyxoah.com

The forward P/S reflects the ratio of the current market value of Nyxoah S.A. (NYXH) to expected annual sales, allowing for an assessment of the extent to which future growth is priced in. By analyzing the projected P/S value, an investor can determine whether the high valuation is justified by the expansion rates of implantable neurostimulators for the treatment of apnea purchased by clinics and insurance funds.

Analysis of competing companies

Price-to-Projected Revenue Ratio Intuitive Surgical Inc ISRG|Forward P/S Multiple Danaher Corporation Inc. DHR|BDX - Price-to-Projected Revenue Ratio|STERIS plc (STE) - Forward Price-to-Revenue Multiple|WST: Forward P/S Multiple|Market Cap to Future Revenue Ratio Baxter International Inc. (BAX)|MASI (masimo.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group Corp STVN|Forward Price-to-Revenue Multiple TFX (Teleflex Inc)|Merit Medical - Market Cap to Projected Revenue|Envista Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICUI (ICU Medical Inc)|XRAY - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio LeMaitre Corp LMAT|ATRC: Forward P/S Multiple|STAA - Market Cap to Expected Sales Ratio|NAGE (Chromadex Corp) - Forward P/S Multiple|ZimVie Inc (ZIMV) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ANGO|CERS (Cerus Corporation) - Forward Price to Sales|Forward P/S Multiple TKNO (Alpha Teknova, Inc.)|Monogram Technologies (MGRM) - Market Cap to Future Revenue Ratio|STSS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio InfuSystem INFU|Utah Med (UTMD) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple KORU Medical Systems, Inc.|Price-to-Projected Revenue Ratio Microbot Medical, Inc.|Market Cap to Projected Revenue PDEX (Pro-Dex)|Price-to-Projected Revenue Ratio Zentek (ZTEK)|Market Cap to Expected Sales Ratio Elutia Inc|Forward P/S Multiple MLSS (milestonescientific.com)|NXGL: Market Cap to Projected Revenue|Retractable Tech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Harvard Bioscience Inc. HBIO|FEMY: Forward P/S Multiple|MeihuaMed - Forward Price to Sales|Price-to-Projected Revenue Ratio Predictive Oncology Inc|callanjmb.com (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corporation (ATRI)|Market Cap to Expected Sales Ratio neurometrix.com